Company Overview and News

 
Skin Elements is well positioned in a growing market

2017-11-26 proactiveinvestors.com.au
Skin Elements (ASX:SKN) is a growing natural and organic skin care company positioned within a US$130 billion global cosmetic market that continues to trend towards natural products. 
Upvote Downvote

 
Business community mourns death of David Humann

2017-11-21 businessnews.com.au
Mincor Resources has announced the passing of its founding chairman David Humann after a short battle with illness.
Upvote Downvote

 
Skin Elements at the forefront of natural, organic skin care products

2017-11-10 proactiveinvestors.com.au
Skin Elements focuses on natural and organic skin care products as an alternative to current chemical-based products.
Upvote Downvote

 
Skin Elements attracts Speculative Buy from broker with four-bagger potential

2017-11-01 proactiveinvestors.com.au
Skin Elements Ltd (ASX:SKN) is focused on the development of natural and organic skin care products.
Upvote Downvote

 
Skin Elements eyes natural cosmetics market in China

2017-10-18 proactiveinvestors.com.au
Skin Elements Ltd (ASX:SKN) has entered into a joint venture agreement with Ageless Products Pty Ltd to distribute the Skin Elements’ product range into China and other major global markets.
Upvote Downvote

 
Skin Elements buys McArthur Skincare

2017-04-19 businessnews.com.au
Recently ASX-listed Skin Elements has acquired a Perth-based therapeutic and cosmetic skin care products company for $1 million in cash and scrip.
Upvote Downvote

 
Skin Elements, AssetOwl to list

2017-01-05 businessnews.com.au
The tail end of the tech stock listing boom will continue tomorrow when two companies start trading on the ASX, with one completing its IPO nearly three years after it first announced listing plans and the other completing a reverse takeover in a relatively efficient five months.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...